WeLeader Biomedical Co., Ltd. (TPEX:7713)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
73.50
+0.60 (0.82%)
Aug 26, 2026, 1:13 PM CST

WeLeader Biomedical Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
249.24208.56170.21152.28153.8105.77
Depreciation & Amortization
130.08124.16108.58103.8109.82114.44
Loss (Gain) From Sale of Assets
0.31-0.021.69-0.69-0.41
Loss (Gain) From Sale of Investments
-2.9-0.15-0.4-0.10.68-0.01
Stock-Based Compensation
-1.61-0.184.233.65
Provision & Write-off of Bad Debts
0.03-0.10.06-0.48-0.530.39
Other Operating Activities
11.65-0.59-6.84-19.568.4112.49
Change in Accounts Receivable
-65.94-46.63-5.75-3.1721.59-47.61
Change in Inventory
-5.41-18.78-29.81-5.77-7.1-13.37
Change in Accounts Payable
6.520.3940.35-12.09-5.3743.39
Change in Unearned Revenue
0.273.671.19-0.36-1.251.02
Change in Other Net Operating Assets
4.4421.161.1415.43-3.318.27
Operating Cash Flow
329.16313.3278.76231.86280.27238.03
Operating Cash Flow Growth
8.34%12.39%20.23%-17.27%17.75%-

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-144.91-212.74-170.71-114.73-659.36-21.6
Sale of Property, Plant & Equipment
1.29--0.951.060.42
Sale (Purchase) of Intangibles
-5.55-1.01-3.56-1-2.29-2.3
Investment in Securities
-36.98-61.66-22.390.83-4.6820.77
Investing Cash Flow
-186.14-275.4-196.65-113.96-665.28-2.71

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-807922424753
Long-Term Debt Issued
-625.01193.13-29120
Total Debt Issued
683.01705.01272.1322453873
Short-Term Debt Repaid
--160-56-288.03-178.97-122
Long-Term Debt Repaid
--605.21-122.33-91.64-118.66-154.6
Total Debt Repaid
-679.33-765.21-178.33-379.67-297.63-276.6
Net Debt Issued (Repaid)
3.68-60.2193.8-155.67240.37-203.6
Issuance of Common Stock
0.02238.22-61.48143.64-
Common Dividends Paid
-186.46-153.17-95.63-29.75-9.77-22.36
Other Financing Activities
2.24----0.02-
Financing Cash Flow
-180.5224.85-1.83-123.94374.22-225.96

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
-37.562.7480.28-6.03-10.799.35

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
184.25100.56108.06117.13-379.09216.43
Free Cash Flow Growth
27.03%-6.94%-7.75%---
Free Cash Flow Margin
15.24%9.06%10.90%12.45%-36.60%25.73%
Free Cash Flow Per Share
3.712.162.592.85-12.467.70
Levered Free Cash Flow
42.9349.3867.88106.57-412.67-
Unlevered Free Cash Flow
51.7554.3971.51110.13-410.04-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
10.0913.8414.9413.66.426.31
Cash Income Tax Paid
50.6547.1243.151.7428.4411.83
Change in Working Capital
-60.14-20.197.12-5.954.561.7